[1]李秋涟,刘翠*,陈丹丹①,等.术前同步放化疗与新辅助化疗治疗局部晚期宫颈癌的临床疗效比较[J].中国微创外科杂志,2018,18(8):707-710.
　Li Qiulian*,Liu Cui*,Chen Dandan,et al.Comparison of Concurrent Preoperative Chemoradiotherapy and Neoadjuvant Chemotherapy for Patients With Locally Advanced Cervical Cancer[J].Chinese Journal of Minimally Invasive Surgery,2018,18(8):707-710.
点击复制

术前同步放化疗与新辅助化疗治疗局部晚期宫颈癌的临床疗效比较()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
18
期数:
2018年8期
页码:
707-710
栏目:
临床研究
出版日期:
2018-10-30

文章信息/Info

Title:
Comparison of Concurrent Preoperative Chemoradiotherapy and Neoadjuvant Chemotherapy for Patients With Locally Advanced Cervical Cancer
作者:
李秋涟; 刘翠*; 陈丹丹①; 林海超②; 廖广界③
广西壮族自治区玉林市红十字会医院妇科二区，玉林537000
Author(s):
Li Qiulian*;  Liu Cui*;  Chen Dandan;  et al.
*Department of Gynecology Ward Ⅱ, The Red Cross Hospital of Yulin, Yulin 537000, China
关键词:
宫颈癌; 放化疗; 新辅助化疗
Keywords:
Cervical cancer; Chemoradiotherapy; Neoadjuvant chemotherapy
文献标志码:
A
摘要:
目的比较术前同步放化疗与新辅助化疗在局部晚期宫颈癌（Ⅰb2～Ⅱb期)治疗中的疗效。方法对我院2010年1月～2011年12月68例Ⅰb2～Ⅱb期宫颈癌，医生根据经验和病人意愿分成术前同步放化疗组（n=32）和新辅助化疗组（n=36），治疗结束后3周评价疗效，肿瘤消退或明显缩小的患者行开腹根治性手术。结果同步放化疗组临床有效率为781%(25/32)，其中CR 28.1%(9/32)，PR 50.0%(16/32)，新辅助化疗组临床有效率66.7%(24/36)，其中CR 11.1%(4/36)，PR 55.6%(20/36)，2组有效率比较差异无统计学意义(χ2=1.105,P=0.293)。同步放化疗组脉管癌栓发生率明显低于新辅助化疗组（2 vs 9， χ2=4.392，P=0.036）。2组淋巴结转移（χ2=1.259，P=0.262）、深肌层浸润（χ2=0.066，P=0797）、宫旁转移(χ2=0.027，P=0.869)无统计学意义。2组患者3、5年总生存率和无瘤生存率无统计学差异（χ2=0.047，P=0.829； χ2=0.001，P=0.976）。结论对于局部晚期宫颈癌，术前同步放化疗与新辅助化疗的疗效无明显差异，术前同步放化疗是可供临床选择的一种治疗方法。
Abstract:
ObjectiveTo compare the effect of concurrent preoperative chemoradiotherapy and neoadjuvant chemotherapy (NACT) for patients with stage Ⅰb2-Ⅱb cervical cancer.MethodsA total of 68 cases of stage Ⅰb2-Ⅱb cervical cancer treated in our hospital from January 2010 to December 2011 were collected. The patients were divided into either concurrent preoperative chemoradiotherapy group (n=32) or NACT group (n=36) according to their own willingness and doctor’s suggestions. The patients with tumor regression obviously underwent radical hysterectomy at 3 weeks after therapy.ResultsThe clinical effective rate was 78.1% (CR 28.1%, PR 50.0%) in preoperative chemoradiotherapy group and 66.7% (CR 11.1%, PR 55.6%) in NACT group. There was no statistically significant difference between the two groups in the clinical effective rate (χ2=1.105, P=0293). Lymphovascular space invasion (LVSI) was significantly lower in the NACT group(2 cases vs. 9 cases, χ2=4.392, P=0036). There was no statistically significant difference in lymph node metastasis (χ2=1.259, P=0.262), deep stromal invasion rate (χ2=0.066, P=0.797) and positive parametrial involvement (χ2=0.027, P=0.869). Overall survival (OS) and disease-free survival (DFS) were similar in the two groups (χ2=0.047, P=0.829; χ2=0.001, P=0.976).ConclusionsConcurrent preoperative chemoradiotherapy and neoadjuvant chemotherapy have similar effects for locally advanced cervical cancer. Preoperative chemoradiotherapy is a treatment method in the clinical treatment of locally advanced cervical cancer.

参考文献/References:

[1]Siegel RL， Miller KD，Jemal A. Cancer Statistics, 2017. CA Cancer J Clin,2007,67(1):7-30.
[2]周晖,刘昀昀,林仲秋,等.2017年NCCN宫颈癌临床实践指南指导解读.中华实用妇科与产科杂志,2017,33(1):100-107.
[3]张艳明，张东峰.放化疗联合治疗中晚期宫颈癌64例疗效观察.中国辐射卫生,2011,20（2）:245-246.
[4]王敏，陶陶，王欣彦.年轻早期宫颈癌患者手术保留卵巢相关问题.中国实用妇科与产科杂志, 2015,31(6):503-507.
[5]胡艳，谭小勇，余红君.同步放化疗治疗中晚期宫颈癌的临床效果及对免疫功能、认知功能的影响分析.中国医学前沿杂志(电子版)，2015，7(12)：5-9.
[6]孟晓红.同步放化疗与单纯放疗治疗中晚期宫颈癌的临床疗效比较.中国医药导刊,2016,14(7):1168-1169.
[7]王亚玲，张艺，陈珏，等.术前同步放化疗治疗局部中晚期宫颈癌的临床疗效.肿瘤学杂志,2017,23(3):241-243.
[8]张昕蕾，张军，蔡有芹. 腹腔镜手术治疗108例宫颈癌的临床分析.中国微创外科杂志,2016,16（11）:980-982.
[9]Jemal A，Simard EP，Dorell C，et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV) associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst,2013,105(3):175-201.

备注/Memo

备注/Memo:
*通讯作者，E-mail:99667345@qq.com①（广西壮族自治区妇幼保健院妇科，南宁530021）②（广西壮族自治区玉林市红十字会医院放疗科，玉林537000）③（广西壮族自治区玉林市红十字会医院病理科，玉林537000）
更新日期/Last Update: 2018-10-30